


































Impact on the phased abolition of co-payments on the utilisation of
selected prescription medicines in Wales






Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Alam, M. F., Cohen, D., Dunstan, F., Hughes, D., & Routledge, P. A. (2018). Impact on the
phased abolition of co-payments on the utilisation of selected prescription medicines in Wales.
Health Economics, 27(1), 236-243. https://doi.org/10.1002/hec.3530
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.




IMPACT OF THE PHASED ABOLITION OF CO-PAYMENTS ON THE 
UTILISATION OF SELECTED PRESCRIPTION MEDICINES IN WALES  
 




We have taken advantage of a natural experiment to measure the impact of the phased abolition 
of prescription co-payments in Wales. We investigated three study periods covering the phased 
abolition: from £6 to £4, £4 to £3 and £3 to £0.  A difference-in-difference modelling was 
adopted and applied to monthly UK general practice level dispensing data on 14 selected 
medicines which had the highest percentage of items dispensed subject to a co-payment prior 
to abolition.  Dispensing from a comparator region (North East of England) with similar health 
and socio-economic characteristics to Wales, and where prescription co-payments continued 
during the study periods, were used to isolate any non-price effects on dispensing in Wales. 
Results show a small increase in dispensing of 14 selected medicines versus the comparator. 
Compared with NE England, monthly average Welsh dispensing was increased by 11.93 items 
(7.67%; 95% CI:  7.2% to 8.1%), 6.37 items (3.38%; 95% CI: 2.9% to 3.7%) and 9.18 items 
(4.54%; 95% CI: 4.2% to 4.9%) per practice per 1000 population during the periods when co-
payment was reduced. Price elasticities of the selected medicines utilisation were -0.23, -0.13 







Globally, there has been a substantial growth in government health expenditure due to 
increased health care costs (Dieleman et al., 2016).  To offset some of these costs, co-payment 
systems have been an aspect of healthcare in many countries (Austvoll-Dahlgren et al., 2008), 
including the UK, where co-payment for prescription medicines has been in the form of a flat 
fee per item dispensed to NHS patients. 
 
A unified approach to prescription co-payment had been applied across all parts of the UK 
(England, Wales, Scotland and Northern Ireland) up to 2000 when the Welsh Assembly 
Government froze the co-payment at its then current level of £6 per item.  A phased reduction   
began in October 2004, with abolition in April 2007.  During this period, the co-payment 
increased steadily in nominal terms in other parts of the UK, but in real terms was virtually 
constant. 
<Figure I here> 
 
  Assessment of the effects of the Welsh policy provided two unique opportunities.  First, 
whereas all previous studies in the UK and most other countries examined the effects of 
increasing costs to patients, the new Welsh policy allowed examination of the effects of 
reducing and ultimately abolishing them.  Second, the Welsh policy provided a natural 
experiment which, for the first time, allowed a comparison of dispensing rates between a 
geographical area which experienced a significant change in the co-payment with another 




The international literature consistently shows that an increase in co-payment leads to a 
decrease in the probability of prescription use, the number of drugs utilised and prescription 
drugs expenditures (Goldman et al., 2007; Leibowitz et al., 1985; McManus et al., 1996; 
Tamblyn et al., 2001; Lexchin and Grootendorst, 2004).  Price elasticity of utilisation is a 
common, unitless measure which describes the responsive of demand for prescription 
medicines (Gemmill et al., 2008). The relationship between co-payment and drug utilization 
can be seen in reviews by Barnieh et al. (2013), Gemmill et al. (2008) and Gibson et al. (2005).  
Several previous studies have estimated the price elasticity of prescription medicines utilisation 
in the UK mainly using national–level, aggregated dispensing data and producing price 
elasticity estimates ranging from -0.64 to -0.09 (Ryan and Birch, 1991; Lavers, 1989; Hughes 
and McGuire, 1995; O’Brien, 1989).   While estimates from other countries are mainly in line 
with this (Puig-Junoy, 1988; Van Vliet, 1999; Smith, 1993; Motheral and Henderson, 1999; 
Klick and Stratmann, 2005; Street et al., 1999; Fiorio and Siciliani, 2010; Grootendorst and 
Levine, 2001), there remains significant heterogeneity, since the type of data used, method of 
analysis applied, subpopulations considered and other factors vary across studies (Gemmill et 
al., 2008).  
 
 Although in the UK prescriptions for certain medical conditions are exempt from co-
payment, most exemptions relate to individuals regardless of their condition. These include 
inter alia older people, children, pregnant women, NHS in-patients and those receiving various 
forms of income support. As a result approximately half the UK population has always been 
exempt from co-payment (Walley, 1998).  In 2003/4, 89% of items dispensed in the community 
in Wales were not subject to co-payment (Health Solutions Wales, 2004).  Any effect of policy 
changes on total dispensing   would therefore be mitigated by the fact that dispensing of most 




We aimed to estimate the relationship between changes in prescription co-payments and 
changes in dispensing rates in Wales during the period October 2003 to March 2008 focussing 
on those medicines which had the highest number of items dispensed with a co-payment prior 




The utilisation of prescription medicines is clearly not solely a function of price and previous 
studies have included a range of other variables including ‘price of substitutes’, ‘sickness 
benefit’, ‘working population’, etc. We avoided any assumptions of confounding effects by 
using North East England as a comparator area which closely resembles Wales in terms of key 
health and socioeconomic characteristics (Table I).  Further, we surveyed all Health Boards in 
Wales and all Primary Care Trusts in NE England (essentially the bodies which receive funding 
to secure or provide health care to those living in defined geographical areas) to identify any 
differences in local prescribing policies and initiatives which could have differentially 
impacted on dispensing rates.  Although there was evidence of some local factors that might 
have influenced dispensing rates, responses from both areas were broadly in accord (Cohen et 
al., 2010).  We could therefore conclude that the influence on dispensing rates of all factors 
other than price was likely to be similar for the two areas over the period of study.  <Table I 
here> 
 
We selected the 14 medicines (strictly, 15 but with two strengths of amoxicillin; Table II) 
from a list of the 100 dispensed medicinal preparations that most frequently incurred a co-
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payment in Wales in April 2005. No medicine had more that 25% of items dispensed subject 
to co-payment in Wales that year.  A minimum percentage of items dispensed subject to co-
payment (4%) was used to ensure representation of treatments for a range of conditions, both 
chronic and acute, and included products also available without prescription, although at 
reduced dose, under supervised sale at community pharmacies: omeprazole (10mg only), co-
codamol (8mg codeine/500mg paracetamol only) and simvastatin (10mg only).    
<Table II here> 
 
 GP practices in Wales were considered as being ‘treated’ by the changes in co-payment 
policy (intervention), while practices in NE England were not (control). We employed a 
difference-in-difference (DiD) approach (Cameron, 2005; Blundell and MaCurdy, 1999) to 
measure this effect. During the course of phased abolition, a total of four interventions took 
place: a reduction from £6 to £5, £5 to £4, £4 to £3 and £3 to £0.  The second intervention 
(from £5 to £4) took place in April 2005 which was only six months after the first intervention 
in October 2004. The remaining two interventions occurred yearly thereafter. We considered a 
12-month pre-intervention and 12-month post-intervention period. For consistency, we 
excluded the six month time window of the second intervention period (October 2004 to March 
2005) from the analysis.    
 
2.1 . ANALYSIS 
 
The econometric model is shown in equation (1) using 24 months practice-level time series 
dispensing data. The outcome, Yit, measures the dispensing rate (number of items per 1000 
population) dispensed by practice i in month t, and is modelled as a function of practice fixed 
effects (ui ) and time fixed effects (vt ) and random error term with zero mean (εit). We define 
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a variable AREAit which takes a value 1 if the practice is in Wales and another variable INTVit 
which equals 1 if the observation belongs to the period after the policy intervention.   
 
Yit = α1 + ui + vt + ws + δ INTVit + λ AREAit + γ AREAit * INTVit + εit  (1) 
 
The time fixed effects are months over two-year time-window that are represented by 23 
dummy variables, with October 2003 being the reference category. The use of monthly 
dummies in model (1) accounts for time trends and their coefficients show how the mean 
dispensing rates change over time, conditional on practice effects. The model is also adjusted 
for season, ws (3 quarterly dummies, with ‘October to December’ being considered as the 
reference category and not included in the model).  The coefficient of the interaction term, γ, 
indicates how dispensing rates differed between Wales and NE England in the last 12 months 
after the policy intervention, conditional on the practice and time effects.   
 
The variance of a practice dispensing rate is inversely proportional to practice list size and these 
varied substantially between practices, hence model (1) is weighted by list size.  The effect is 
to give more weight to large practices whose rates are likely to show smaller random 
fluctuations than small practices. 
As a DiD approach assumes that trends in intervention and control areas are similar before 
introducing the intervention, we carried out a pre-trends test over 3 separate pre-intervention 
time periods (1 = October 2003 to September 2004, 2 = April 2005 to March 2006, 3 = April 
2006 to March 2007) in line with Sutton et al. (2012), and given in equation (2).   
 




where t represents the month since the start of the data point, β is an estimate of the monthly 
trend in NE England and ρ is the difference in monthly trend between Wales and NE England. 
The null hypothesis is that  = 0.  
The regression models were estimated using a weighted least-square method, with robust 
standard error corrected for heteroscedasticity. A crude price elasticity of prescription 
medicines utilisation in Wales was then calculated using the formula,  
Price elasticity = 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒𝑠 𝑢𝑡𝑖𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑐𝑜−𝑝𝑎𝑦𝑚𝑒𝑛𝑡
  
 
Since the study investigated interventions covering three time windows, our Analysis 1 
covers a study period of two years when co-payment was £6 and £4, Analysis 2 covers a study 
period of two years when co-payment was £4 and £3 and, finally, Analysis 3 covers a study 
period of two years when co-payment was £3 and £0 in Wales. 





 Health Solutions Wales (HSW) provided practice list size and practice-level monthly 
dispensing volume data for the 14 selected medicines, for all practices in Wales (N = 485). The 
Prescription Pricing Authority (PPA) provided comparable data for all practices in NE England 
(N = 393).  We included all practices and months during October 2003 to September 2004 and 
April 2005 to March 2006 in our first analysis (analysis 1). Similarly, all practices and months 
during April 2005 to March 2007 are in analysis 2 and all practices and months during April 
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2006 to March 2008 are in analysis 3, producing a total of 878 x 24 = 21,072 observations in 
each analysis. The same sample of practices has been used in all three analyses. Table III 
provides descriptive statistics of dispensing and co-payment data for three analyses covering 
study periods defined in section 2. 
 





 Results from pre-trends testing suggest that we were not able to reject the null hypothesis in 
all three analyses (ρ = 0.43 (95% CI: -3.4 to 4.3), ρ = 0.84 (95% CI: -3.5 to 5.2) and ρ = 1.4 
(95% CI: -3.3 to 6.1) in Analyses 1, 2 and 3 respectively). 
 
Table III shows that monthly dispensing of 14 selected medicines increased after the 
intervention in all three analyses and in both areas. However, the increase was greater in Wales 
than in NE England (33.1, 13.73 and 14.02 items (per practice per 1000 population) versus 
21.21, 7.05 and 4.36 items in Analyses 1, 2 and 3 respectively.   
 
The DiD model suggests that, compared to NE England, Welsh dispensing increased in all 
analyses (p<0.0001), however, the increase was smaller in Analysis 2 when co-payment was 
reduced to £3 from £4 (Table IV).  
 
The 11.93 items (per practice per 1000 population) increase in Welsh dispensing of 14 
selected medicines is equivalent to roughly 7.7% increase of the average Welsh dispensing 
9 
 
during the period when prescription co-payment was £6 and £4 (Analysis 1, Table V). 
Corresponding increases in Analyses 2 and 3 were 3.4% and 4.5%, respectively.  
 
  We estimated a crude price elasticity of medicines utilisation as  -0.23, -0.13 and -0.04 
from Analyses 1, 2 and 3 respectively.  
 





Our results suggest that the effect on dispensing of changing co-payment levels is not 
negligible. The Welsh policy was introduced with an explicit aim to improve health through 
removal of a (perceived) obstacle to those on low incomes obtaining the medicines they need 
(WAG, 2003). There is evidence that co-payment poses a barrier to adherence to treatment 
(Schafheutle, 2003).  The increase in dispensing rates for the 14 selected medicines therefore 
suggests that there may have been a group of non-exempt patients in Wales who were not fully 
adherent with prescribed treatment before the policy was introduced. The policy may therefore 
have contributed to reducing patients’ non-adherence which in principle should produce an 
increase in health. A separate study undertaken by the authors suggested that the Welsh policy 
did not have an impact on consumption of medicines available without prescription from 
pharmacies (Groves et al, 2010). 
 
The price elasticity of utilisation estimates of -0.23, -0.13 and -0.04 for the three study 
periods respectively suggest that by the time the co-payment had fallen to a very low level (£3 
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per item), much of the effect had already occurred and a further fall to zero (abolition) had a 
lesser impact on dispensing rates than the earlier reductions.  
 
Our study suggests that the utilisation of prescription medicines in Wales is inelastic and 
implies that consumers are not particularly responsive to changes in co-payments at these 
levels. This is not uncommon for a tax-financed health care system such as that in the UK, 
suggesting that consumers in publicly funded health systems appear to be less sensitive to 
changes in out-of-pocket expenses than consumers in other types of insurance systems 
(Gemmill et al., 2008).    
 
The low price elasticity estimates here may be due to several factors.  Firstly, those patients 
whose utilisation is likely to be most sensitive to changes in price i.e. those on very low 
incomes, were already exempt from co-payment.  Secondly, elasticity is commonly estimated 
for small changes in price; here the reductions happened in relatively large increments.   
 
One advantage of our study was its ability to exploit a situation in which the policy on 
prescription co-payment changed in one area while remaining virtually constant in real terms 
in another with similar populations and local prescribing policies. Thus differences in 
dispensing could reasonably be assumed to be due to the Welsh policy on price.  A 
disadvantage of our study, however, was the omission of the 6 month period when the 
prescription charged moved from £5 to £4, which may have coincided with the highest price 
elasticity of utilisation. There may also be unobserved confounding factors that were not 







Abolition of co-payments has had a positive but small effect on dispensing rates in Wales.  The 
magnitude of the impact of reductions in co-payment shown in this study appears to be broadly 
similar to those of increases in co-payment shown from previous studies. Use of a comparator 
area avoided the need to use questionable proxies to account for confounding variables but this 
approach is only possible in rare situations.  
Disaggregating the data into three time periods showed most of the effect occurred in 
response to the earlier reductions from relatively high levels. The response to abolishing a co-
payment which has already fallen to a low level is less.  Our study presents evidence that could 
support more detailed descriptions of underlying processes and qualitative analyses to help 
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Figure 1. Per item prescription co-payment in Wales, England, Scotland and Northern 


















Table I. Key health and economic statistics: Wales v NE England 
 Wales NE England 
% Reporting good health, 2001 65 64 
% Reporting not good health, 2001 12 12 
Standardised Mortality Ratio, 2003 105 113 
Life expectancy at birth - males, 2001 75.5 74.7 
Life expectancy at birth - females, 2001 80.1 79.5 
% Population with limiting long term illness, 2001 23 23 
% Population with no qualifications, 2004 24 25 
% Population claiming income support 8 9 
Unemployment rate (%), 2005 5.3 6.2 
% Population claiming incapacity benefit/severe 
disability rate 
7 7 
Average weekly household total income (£) 410 410 
% Population claiming disability allowance, 2002 7 6 












Table II. Monthly number of items dispensed in Wales (14 selected medicines): April, 2005 
 
Medicine Total Exempt Percentage Paid1 
Phenoxymethylpenicillin tablets 
250mg 
11,797 9,039 23.38 
Amoxicillin capsules 500mg (*) 21,647 16,821 22.29 
Erythromycin e/c tablets 250mg (**) 13,706 10,882 20.60 
Diclofenac e/c tablets 50mg (**) 17,342 13,851 20.13 
Amoxicillin capsules 250mg (*) 41,422 33,102 20.09 
Citalopram tablets 20mg 13,172 10,606 19.48 
Fluoxetine capsules 20mg 24,349 19,783 18.75 
Trimethoprim tablets 200mg 12,986 10,659 17.92 
Co-codamol tablets  30mg/500mg 10,417 9,291 10.81 
Salbutamol inhaler 100mcg (200 
doses) 
32,914 29,384 10.72 
Atenolol tablets 50mg 45,454 40,660 10.55 
Lansoprazole e/c capsules 15mg (**) 23,030 20,753 9.89 
Omeprazole e/c capsules 20mg (**) 23,402 21,431 8.42 
Bendroflumethiazide tablets 2.5mg 83,094 76,571 7.85 
Simvastatin tablets 20mg 22,605 21,611 4.40 
 Source: Health Solutions Wales (personal communication) 
1.  Number of items dispensed subject to co-payment/ Total number of items dispensed. 
(*)  The two strengths for amoxicillin were analysed separately but are considered a single 
medicine among the 14 medicines selected for this study.   





Table III. Descriptive statistics of monthly dispensing items (per practice per 1000 
population) and average co-payment 
 October 2003 to September 2004 
 Wales NE England 
 No. of 
observations 
Mean SD No. of 
observations 
Mean SD 
Dispensing rate 5820 155.54 42.15 4716 159.89 46.59 
Average co-payment 5820 5.99 0.01 4716 6.33 0.05 
 April 2005 to March 2006 
 Wales NE England 
 No. of 
observations 
Mean SD No. of 
observations 
Mean SD 
Dispensing rate 5820 188.64 50.42 4716 181.10 51.91 
Average co-payment 5820 3.99 0.01 4716 6.49 0.02 
 April 2006 to March 2007 
 Wales NE England 
 No. of 
observations 
Mean SD No. of 
observations 
Mean SD 
Dispensing rate 5820 202.37 53.34 4716 188.15 54.06 
Average co-payment 5820 2.99 0.01 4716 6.62 0.02 
 April 2007 to March 2008 
 Wales NE England 
 No. of 
observations 
Mean SD No. of 
observations 
Mean SD 
Dispensing rate 5820 216.39 56.61 4716 192.51 56.55 
Average co-payment 5820 0.00 0.00 4716 6.83 0.03 
Note: Co-payment is deflated by monthly Retail Price Index. During a year, the total number 
of observations for ‘Wales’ is 5820 (all practices in Wales, 485 x 12) and the total number of 





Table IV. Difference-in-difference estimates, before and after introduction a change in co-







Analysis 1 11.93a 11.21 to 12.65 <0.0001 
Analysis 2 6.37a 5.75 to 6.99 <0.0001 
Analysis 3 9.18a 8.52 to 9.83 <0.0001 
Note: Analysis 1 covers two years of study period when co-payment in Wales was £6 and £4. 
Analysis 2 covers two years study period when co-payment in Wales was £4 and £3. Analysis 
3 covers two years study period when co-payment in Wales was £3 and £0. a Monthly 
number of items dispensed  per practice per 1000 population. “Seas 1” (October to December 
=1, else=0) is a reference category dummy, not included in the model. 
 
Table V. Price elasticity of medicines utilisation in Wales during three study periods 
 
 Percentage change in 
medicines utilisation in 
Wales 
Percentage change in 
co-payment in Wales 
Price elasticity 
Analysis 1 + 7.67%  -33.39% - 0.23 
Analysis 2 + 3.38% -25.06% - 0.13 
Analysis 3 + 4.54% -100.0% - 0.04 
Note: Analysis 1 covers two years of study period when co-payment in Wales was £6 and £4. 
Analysis 2 covers two years study period when co-payment in Wales was £4 and £3. Analysis 
3 covers two years study period when co-payment in Wales was £3 and £0. 
